J&J Draws Line On Procrit Pricing; Will Not Match Amgen Aranesp 40% Discounts
This article was originally published in The Pink Sheet Daily
Executive Summary
Procrit sales are the one weak spot in a strong quarter overall. J&J is moving away from its previous policy of retaining a "level playing field" between Procrit and Aranesp pricing; the strategy now is to have a "reasonably level playing field."
You may also be interested in...
Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says
Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.
Procrit Critical Care Label Expansion Could Fuel Franchise Sales, J&J Says
Johnson & Johnson remains committed to the anemia agent despite failing to return the franchise to growth in 2005.
Procrit Could Return To Growth Later This Year, J&J Says
Anemia therapy should reverse a quarterly sales decline brought on by competition from Amgen, Johnson & Johnson maintains. Worldwide sales were up for the second quarter.